Recombinant Human SLAM/CD150 Fc Chimera Protein, CF

Catalog #: 11480-SL Datasheet / COA / SDS

SLAMF1

Catalog #	Availability	Size / Price	Qty
11480-SL-050

Recombinant Human SLAM/CD150 Fc Chimera Protein Binding Activity.

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human SLAM/CD150 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. Recombinant Human SLAM/CD150 Fc Chimera binds to Biotinylated SLAM/CD150 protein with an ED₅₀ of 0.100-1.00 μg/mL.

Source

Human embryonic kidney cell, HEK293-derived human SLAM/CD150 protein

Human SLAM (Ala21-Lys236) Accession # Q13291.1	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

Q13291.1

N-terminal Sequence
Analysis

Ala21,Tyr23,Thr25

Predicted Molecular Mass

51 kDa

SDS-PAGE

60-80 kDa, under reducing conditions.

Product Datasheets

11480-SL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11480-SL

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

Recombinant Human SLAM/CD150 Fc Chimera Protein (Catalog # 11480-SL) binds to Biotinylated SLAM/CD150 protein with an ED₅₀ of 0.100-1.00 μg/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human SLAM/CD150 Fc Chimera Protein (Catalog # 11480-SL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-80 kDa and 120-160 kDa, respectively.

Reconstitution Calculator

Background: SLAM/CD150

Signaling lymphocytic activation molecule (SLAM), also known as SLAMF1 and CD150, is the founding member of the SLAM subfamily of the CD2 protein family (1, 2). SLAM is a single-pass type I membrane glycoprotein that functions as an adhesion molecule and plays an active role in the regulation of innate and adaptive immunity (1, 2, 4). Mature SLAM consists of an extracellular domain (ECD) containing an Ig-like V-type domain and an Ig-like C2-type domain, a helical transmembrane domain, and a cytoplasmic tail containing 2 immunoreceptor tyrosine-based switch motifs (ITSM) (3, 4). The ECD of human SLAM shares human SLAM shares 58% and 56% amino acid sequence identity with mouse and rat SLAM, respectively.. In human, several isoforms resulting from alternative splicing have been identified with functional diversity (4). SLAM is expressed on T cells, B cells, thymocytes, macrophages, dendritic cells, platelets, and hematopoietic stem cells, and it is up-regulated on activated B cells and CD4+ and CD8+ T cells (4 – 6). SLAM interacts homophilically with low affinity, and this interaction induces a Th0/Th1 phenotype in CD8+ T cells that is characterized by clonal expansion, production of IFN-gamma, and increased cytolytic activity (7, 8). SLAM also plays a role in activation of the PI3K-Akt signaling pathway through its association with the adapter molecule SAP (9). In humans, SLAM functions as a cellular entry receptor for measles virus (10, 11). SLAM deregulation is associated with genomic complexity and independently predicts a worse outcome in chronic lymphocytic leukemia (CLL) (12).

References

Yurchenko, M. et al. (2018) J. Cell. Biol. 217:1411.
Pellegrini, J. et al. (2021) Autophagy. 17:2629.
Wang, N. et al. (2015) Front. Immunol. 6:158.
Gordiienko, I. (2019) Clinical Immunol. 204:14.
Calpe, S. et al. (2008) Adv Immunol. 97:177.
Wang, N. et al. (2004) J. Exp. Med. 199:1255.
Mavaddat, N. et al. (2000) J. Biol. Chem. 275:28100.
Mehrle, S. et al. (2008) Mol. Immunol. 45:796.
Yurchenko, M.Y. et al. (2005) Exp Oncol. 27:24.
Hsu, E.C. et al. (2001) Virology 279:9.
Gonçalves-Carneiro, D. et al. (2017) J Virol. 91:e02255.
Gian, M.R. et al. (2021) Br. J. Haematol. 192:1068.

Long Name

Signaling Lymphocytic Activation Molecule

Entrez Gene IDs

6504 (Human); 27218 (Mouse); 102135470 (Cynomolgus Monkey)

Alternate Names

CD 150; CD150; CD150IPO-3; CDw150; IPO-3; signaling lymphocytic activation molecule family member 1; signaling lymphocytic activation molecule; SLAM; SLAMCD150 antigen; SLAMF1